Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR -Mutated Non-Small-Cell Lung Cancer: Regulatory Considerations.
Bernardo H L GoulartErin LarkinsJulia A BeaverHarpreet SinghPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)